STOCK WATCH

4D PHARMA creates drugs from good bacteria designed to interact with the human microbiome found in the gut.

Called biotherapeutics, they are being developed to treat diseases ranging from cancer to conditions affecting the central nervous system.

Staff are in San Francisco at a conference showcasing promising data from an early-phase trial of a potential new treatment for asthma. The shares were up 1.75p, or 5.3pc, at 35p, valuing the Leeds-based group at just under £65m.